FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare In today’s episode, we’ll cover… The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections and more!To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.To watch the video clips of our podcast, subscribe to our YouTube channel,@EyeOnTech. References: Anticipating the healthcare reach of GLP-1 receptor agonists Are compounded GLP-1 drugs safe? FDA winds down GLP-1 compounding policies